Drug Trial Radar · NCT05049902
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication
Last checked: Nov 19, 2026Latest source record: Jul 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,300
Actual
Start
Sep 21, 2021
Primary completion
May 30, 2023
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- Shandong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Maternity and Child Care Health Center of Dezhou; Heze Municipal 3rd people's hospital; Peking University Care Luzhong Hospital; The People's Hospital of Jimo.Qingdao
- First posted
- Sep 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
Conditions
- Helicobacter Pylori Infection
Interventions
AmoxicillinDrug
Use according to the drug combination options selected by each center.
ClarithromycinDrug
Use according to the drug combination options selected by each center.
TetracyclineDrug
Use according to the drug combination options selected by each center.
MetronidazoleDrug
Use according to the drug combination options selected by each center.
Bismuth Potassium CitrateDrug
Use according to the drug combination options selected by each center.
Colloidal Bismuth PectinDrug
Use according to the drug combination options selected by each center.
Vonoprazan fumarateDrug
Use according to the drug combination options selected by each center.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Eradication rateTime frame: Immediately after follow-up check.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
The People's Hospital of Jimo.Qingdao
Qingdao, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Maternity and Child Care Health Center of Dezhou
Dezhou, Shandong, China
Heze Municipal 3rd people's hospital
Heze, Shandong, China
Qilu hosipital
Jinan, Shandong, China
PKUCare Luzhong Hospital
Zibo, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.